Roland Magnusson/iStock Editorial via Getty Images
- Genetron Holdings (NASDAQ:GTH) has signed a collaboration agreement with AstraZeneca (NASDAQ:AZN) R&D China for the joint development in China of next-generation sequencing-based tumor-informed minimal residual disease (MRD) tests for various solid tumor types.
- AZN plans to incorporate the co-developed tests for China-specific studies.
- Under the agreement, the companies will jointly invest capital for this collaboration, and will work together to develop and validate the personalized, solid tumor MRD assays for cancer monitoring and recurrence in China.
- These assays will be developed based on the genetic analysis of the primary tumor from individual patients at the beginning of treatment. A joint committee will be established to oversee the product development.